<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066789</url>
  </required_header>
  <id_info>
    <org_study_id>CHOICE-4</org_study_id>
    <nct_id>NCT05066789</nct_id>
  </id_info>
  <brief_title>CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4</brief_title>
  <acronym>SMART-CHOICE4</acronym>
  <official_title>Comparison of Polymer-Free Cobalt-Chromium Thin Drug-Coated Stents With Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy With Conventional 12-Month Dual Antiplatelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is multi-center, open label, two-by-two factorial, randomized, noninferiority&#xD;
      trial to compare the efficacy and safety of polymer-free cobalt-chromium thin drug-coated&#xD;
      stents (BioFreedom Ultra) with biodegradable polymer ultrathin sirolimus-eluting stents&#xD;
      (Orsiro Mission) and prasugrel monotherapy after 1-month dual antiplatelet therapy (DAPT) of&#xD;
      aspirin plus prasugrel with 12-month DAPT of aspirin plus prasugrel in patients with acute&#xD;
      coronary syndrome undergoing percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polymer is the key component of drug-eluting stents (DES) for facilitation of drug loading&#xD;
      and control of drug release. However, durable polymer of the 1st generation DES has been&#xD;
      considered to induce inflammation and to be associated with fatal complications such as very&#xD;
      late stent thrombosis. To overcome this shortcoming, biodegradable polymer has been applied&#xD;
      to the DES system. In several head-to-head comparison, ultrathin strut biodegradable polymer&#xD;
      sirolimus-eluting Orsiro stent demonstrated comparable or superior outcomes compared with&#xD;
      durable polymer everolimus-eluting stents. As a result, Orsiro stent is considered one of the&#xD;
      standard contemporary DESs.&#xD;
&#xD;
      On the other hand, polymer-free drug-coated stents (DCS) have been developed as an&#xD;
      alternative to durable and biodegradable polymer DES. The biolimus A9-coated BioFreedom stent&#xD;
      is the representative polymer-free drug-coated stent and was superior to a bare-metal stent&#xD;
      in patients treated with 1-month dual antiplatelet therapy (DAPT). However, it failed to show&#xD;
      noninferiority for major adverse cardiovascular events at 12 months when compared with the&#xD;
      ultrathin strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers&#xD;
      population, mainly due to increased target lesion revascularization (TLR). On top of possible&#xD;
      insufficient or uncontrolled drug delivery at stented site due to absence of a drug carrier,&#xD;
      thick strut (112 µm) and stainless steel alloy may explain a higher rate of TLR in the&#xD;
      BioFreedom stent group compared with the Orsiro stent group. The BioFreedom Ultra stent is a&#xD;
      novel cobalt-chromium thin stent (84 µm) with biolimus A9-coating. With advancement in stent&#xD;
      alloy and strut thickness, treatment efficacy and safety of the BioFreedom Ultra stent would&#xD;
      be comparable to the new version of Orsiro stent (Orsiro Mission) among patients with acute&#xD;
      coronary syndrome (ACS).&#xD;
&#xD;
      Patients with ACS undergoing percutaneous coronary intervention (PCI) with DES are currently&#xD;
      recommended to use 12 months of DAPT, consisting of aspirin and P2Y12 inhibitor. Although use&#xD;
      of DAPT reduces ischemic events, including stent thrombosis, bleeding events increase in&#xD;
      return. Hence, considering the aforementioned advancement of stent devices, shorter duration&#xD;
      of DAPT and switching to a potent P2Y12 inhibitor monotherapy would be possible. This has&#xD;
      been demonstrated in several recent studies. However, although prasugrel was superior to&#xD;
      ticagrelor in lowering ischemic events, these studies mainly used ticagrelor as a solely used&#xD;
      antiplatelet agent, and studies verifying the effect of prasugrel monotherapy after short&#xD;
      duration of DAPT are limited to date. In addition, in these studies, DAPT was maintained for&#xD;
      mostly at least 3 months in the ACS situation. With advancement of devices, duration of DAPT&#xD;
      may be further reduced. In other words, prasugrel monotherapy after 1 month of DAPT of&#xD;
      aspirin plus prasugrel would be comparable to 12-month DAPT of aspirin plus prasugrel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>multi-center, open label, two-by-two factorial, randomized, noninferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent Comparison Study: target-lesion failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>a composite of cardiac death, target vessel-myocardial infarction, or clinically indicated target-lesion revascularization by percutaneous or surgical methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiplatelet Comparison Study: net adverse clinical events (NACE)</measure>
    <time_frame>1 year</time_frame>
    <description>a composite of major adverse cardiac and cerebrovascular events (MACCE) and clinically relevant bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: TLF</measure>
    <time_frame>3 years</time_frame>
    <description>a composite of cardiac death, target vessel-myocardial infarction, or clinically indicated target-lesion revascularization by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: target-vessel failure</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>a composite of cardiac death, target vessel-MI, or clinically indicated target-vessel revascularization by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: cardiac death</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: target-vessel myocardial infarction (MI)</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>target-vessel MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: clinically indicated TLR</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: stent thrombosis</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>definite or probable by Academic Research Consortium [ARC] definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: clinically indicated target-vessel revascularization (TVR)</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>clinically indicated target-vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: cardiac death or MI</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>cardiac death or MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: cardiac death, MI, or stent thrombosis</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>cardiac death, MI, or stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: all-cause death</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: MI</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: all-cause death or MI</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>all-cause death or MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: any revascularization</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Comparison Study: restricted mean survival time for the TLF</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>restricted mean survival time for the TLF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>a composite of all-cause death, MI, and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: all-cause death</measure>
    <time_frame>1 year</time_frame>
    <description>all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: MI</measure>
    <time_frame>1 year</time_frame>
    <description>MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: stroke</measure>
    <time_frame>1 year</time_frame>
    <description>stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: cardiac death</measure>
    <time_frame>1 year</time_frame>
    <description>cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>definite or probable by ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: all-cause death or MI</measure>
    <time_frame>1 year</time_frame>
    <description>all-cause death or MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: cardiac death or MI</measure>
    <time_frame>1 year</time_frame>
    <description>cardiac death or MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: cardiac death, MI, or stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>cardiac death, MI, or stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: BARC type 3 or 5 bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC type 3 or 5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Comparison Study: restricted mean survival time for the NACE</measure>
    <time_frame>1 year</time_frame>
    <description>restricted mean survival time for the NACE</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Biodegradable Polymer DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.&#xD;
This group will use Orsiro Mission stent during the index procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.&#xD;
This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polymer-free DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.&#xD;
This group will use BioFreedom Ultra stent during the index procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.&#xD;
This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Type of stent</intervention_name>
    <description>1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)</description>
    <arm_group_label>Biodegradable Polymer DES</arm_group_label>
    <arm_group_label>Polymer-free DCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duration of DAPT</intervention_name>
    <description>1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)</description>
    <arm_group_label>12-month DAPT</arm_group_label>
    <arm_group_label>Prasugrel monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 19 years of age&#xD;
&#xD;
          2. Subject who is able to understand risks, benefits and treatment alternatives and sign&#xD;
             informed consent voluntarily.&#xD;
&#xD;
          3. Patients presenting with ACS (ST-elevation myocardial infarction [STEMI],&#xD;
             non-ST-elevation myocardial infarction [NSTEMI], or unstable angina)&#xD;
&#xD;
          4. Patients with at least one lesion with equal or greater than 50% diameter stenosis&#xD;
             requiring treatment with drug-eluting stents (DES) in native coronary artery or graft&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to provide consent&#xD;
&#xD;
          2. Patients with known intolerance to aspirin, clopidogrel, prasugrel, or major&#xD;
             components of drug-eluting stents&#xD;
&#xD;
          3. Patients who have non-cardiac co-morbid conditions with life expectancy &lt;1 year or&#xD;
             that may result in protocol non-compliance (per site investigator's medical judgment)&#xD;
&#xD;
          4. Patients who need chronic anti-coagulation therapy&#xD;
&#xD;
          5. Patients with active pathological bleeding&#xD;
&#xD;
          6. Pregnant or lactating women&#xD;
&#xD;
        Additional Exclusion Criteria for Antiplatelet Comparison Study:&#xD;
&#xD;
          1. Patients with history of stroke or transient ischemic attack&#xD;
&#xD;
          2. Patients 75 years of age or older&#xD;
&#xD;
          3. Patients weighing less than 60 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Yong Hahn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo-Yong Hahn, MD, PhD</last_name>
    <phone>82-2-3410-1246</phone>
    <email>ichjy1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ki Hong Choi, MD, PhD</last_name>
    <phone>82-2-3410-3419</phone>
    <email>cardiokh@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Yong Hahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Antiplatelet Therapy</keyword>
  <keyword>Drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

